Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- wetAMD, Age Related Macular Degeneration
- Main trialPhase 2
- “Trial to Evaluate the Safety and Efficacy of SCAI-005 Ophthalmic solution in Patients with Neovascular Age-related Macular Degeneration. The purpose of this study is to investigate the efficacy, safety and tolerability of SCAI-005 Ophthalmic solution by dose in patients with neovascular Age-related Macular Degeneration (nAMD).”In the company’s words, NCT07607561 on ClinicalTrials.gov
Other drugs for Age Related Macular Degeneration
- Surabgene LomparvovecAbbVie · Phase 3
- 4D-150 IVT4D Molecular Therapeutics · Phase 3
- TinlarebantBelite Bio, Inc · Phase 3
- VonaprumentAnnexon, Inc. · Phase 3
- ElamipretideStealth BioTherapeutics Inc. · Phase 3
- ONS-5010Outlook Therapeutics, Inc. · Phase 3
Coming up1
- 31 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 31 Aug 2027 | Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration | |
| Phase 1Completed | 4 Sep 2025 | Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026